RE:RE:RE:RE:Big pharma is set to keep signing bigger deals in 2024Late stage clinical development companies with validating clinical data who seek to advance their biological drug platforms through the Accelerated Approval pathway for early market entry, are the same companies that usually hold high M&A premiums, particualry now that Big Pharma is pursuing M&A to accelerate the replenishment of their product portfolios as the looming patent cliff is upon them. Big Pharma can no longer wait and try to finesse the acquisition of late-state clinical development biotech companies.
With the patent cliff upon them, these same Big Pharma no longer have the benefit of time to develop products in house, (as Roche and Merck have recently found) and will be forced to pay high premiums for late-stage clinical development biotech companies to replenish their impending lost product sales and revenues, ressulting from the loss of market exclusivities that were held by their 'blockbuster' products - and now soon-to-be generic (biosimilar) products.